Federal prosecutors say Michael McMillan embedded alleged wound-care kickbacks within provider agreements, percentage-based invoices, reimbursement-contingent payment terms, and sales-representative commissions, creating commercial-looking relationships that allegedly rewarded medical practices and recruiters when government programs paid skin-substitute claims.
WASHINGTON, D.C., August 23, 2026 — Federal prosecutors accuse Las Vegas businessman Michael McMillan of building an alleged wound-care kickback system that operated through contracts, invoices, corporate entities, and commissioned sales representatives instead of relying principally upon simple envelopes of cash passed directly between participants.
The government’s theory describes a layered commercial structure in which Protectus companies allegedly supplied skin substitutes without upfront charges, medical providers retained predetermined percentages of successful reimbursements, and representatives earned commissions after recruited practices paid Protectus from government-program proceeds.
That structure matters because prosecutors contend the business labels did not change the economic substance of the alleged transactions, while McMillan’s defense can argue that ordinary distribution agreements, discounts, credit terms, and sales compensation possessed legitimate commercial purposes.
The allegations appear within a nine-count federal case involving approximately $268 million in payments from Medicare, TRICARE, and CHAMPVA, approximately $174 million allegedly received by Protectus entities, and approximately $94 million prosecutors characterize as provider kickbacks.
McMillan has not been convicted; every accusation remains subject to adversarial testing, and the government must prove that the challenged agreements represented knowing and willful criminal inducements rather than lawful contracting practices, disputed pricing methods, or regulatory misunderstandings.
The Alleged Intermediary Structure Requires Careful Description
The government does not allege that every provider payment traveled through a sales representative before reaching a clinician, because its account instead describes two related incentive streams operating alongside one another within the broader Protectus business model.
Medical providers allegedly obtained their benefit by retaining approximately thirty to forty percent of successful government reimbursements, while sales representatives allegedly received separate compensation calculated from the money Protectus collected after providers paid their percentage-based invoices.
Under the prosecution’s theory, sales representatives therefore functioned as recruitment intermediaries, connecting Protectus with physicians, podiatrists, nurse practitioners, and other providers while explaining the profit-sharing arrangement that allegedly accompanied use of the company’s skin-substitute products.
That distinction prevents an important factual error, because describing representatives as pass-through conduits for every provider payment would go beyond the charging document, which portrays them primarily as paid recruiters receiving their own reimbursement-linked commissions.
Six Protectus Entities Formed the Corporate Framework
The unsealed federal indictment identifies Protectus LLC, Protectus Technologies LLC, Protectus Consulting LLC, Prestige Medical Consultants LLC, Velare Wound Care LLC, and Amnio ReGen Solutions LLC as Nevada limited-liability companies allegedly owned and controlled by McMillan.
Prosecutors generally refer to those businesses collectively as Protectus, but their individual bank accounts, contracts, invoices, employees, customer relationships, and payment records may become critical when lawyers examine who performed each act and authorized each transaction.
Multiple affiliated companies can serve legitimate operational, tax, licensing, investment, risk-management, or product-distribution purposes, meaning common ownership alone cannot establish that the entities functioned as devices for concealing kickbacks or generating fraudulent healthcare claims.
The prosecution may nevertheless use shared control, coordinated personnel, intercompany movements, common invoicing practices, and McMillan’s alleged approval of representative commissions to argue that the separate entities participated within a centrally directed reimbursement system.
Contracts Allegedly Defined Provider Profit Before Treatment
According to prosecutors, Protectus provided skin-substitute products to participating medical practices without requiring upfront payment, allowing providers to apply expensive wound-care products before assuming the conventional financial risk of purchasing commercial inventory.
Protectus allegedly invoiced a provider only after Medicare or another government program reimbursed the related claim, while a denied claim generated no product charge, making the provider’s financial obligation contingent upon a successful insurance payment.
The indictment says Protectus ordinarily charged only sixty to seventy percent of the reimbursement, leaving the provider with thirty to forty percent and allegedly guaranteeing thousands of dollars in profit whenever a covered skin-substitute claim produced payment.
Federal prosecutors characterize that retained share as unlawful remuneration intended to induce providers to use Protectus products, while the defense may characterize the same economics as discounts, rebates, consignment, credit protection, or commercial risk allocation.
A Contract Email Became an Alleged Overt Act
The charging document highlights a July 2023 email concerning an invoice sent to a Texas physician, whose employee allegedly told McMillan that a new contract promised forty-percent profit even though the invoice appeared to reflect thirty-five percent.
Prosecutors allege McMillan forwarded that message to a Protectus employee and instructed them to correct the discrepancy; they may use that exchange to connect him personally to the percentage retained by a participating medical practice.
The wording is significant because it allegedly frames provider profit as an agreed contractual term rather than an incidental margin discovered after billing, potentially supporting the government’s claim that remuneration was intentionally built into the relationship.
Defense counsel can still dispute the email’s meaning by examining the complete contract, preceding negotiations, product costs, accounting terminology, later amendments, industry practice, and whether the word profit described a lawful discount instead of a prohibited inducement.
Invoices Allegedly Recorded the Division of Reimbursement
One QuickBooks invoice cited in the indictment listed total collections of $53,625.60, stated that a Utah medical provider would keep $16,087.68, and identified $37,537.92 as the amount due to Protectus Technologies under the disputed arrangement.
That document may let prosecutors present the alleged kickback theory through simple arithmetic, showing jurors how a government reimbursement was allegedly split between the billing provider and the distributor after payment arrived.
Invoices can also provide timestamps, account identifiers, product references, payment terms, approving personnel, revisions, and linked communications, creating a documentary trail that investigators can compare against claim submissions, bank deposits, commission reports, and treatment records.
However, an invoice displaying retained revenue does not establish illegality by itself, because commercial distributors routinely use variable pricing, discounts, rebates, credits, and contingent terms whose legality depends upon purpose, disclosure, documentation, and applicable healthcare rules.
Sales Representatives Allegedly Became Recruitment Intermediaries
The indictment identifies four anonymized individuals whom prosecutors describe as sales representatives located in Texas, California, and Utah, while alleging that McMillan hired representatives to recruit medical providers into the challenged skin-substitute arrangement.
Those representatives allegedly explained the profit-sharing system and the resulting provider benefit for each reimbursed product, giving them a central communication role between Protectus management and medical practices considering participation within the distribution network.
Their compensation was allegedly tied directly to reimbursements generated by recruited providers, meaning a representative became eligible for payment only after a government program reimbursed a claim and Protectus collected its portion from the practice.
Prosecutors describe approximately $27 million paid to sales representatives as illegal kickbacks intended to influence medical referrals, although that amount represents compensation from Protectus receipts and should not be added above the approximately $268 million program-payment total.
Commission Reports Allegedly Connected Recruiters with Claims
The indictment describes a November 2022 email disputing one representative’s commission report, alleging that $6,446.55 in compensation was missing after medical practices recruited by that representative received reimbursement for their skin-substitute claims.
A Protectus employee allegedly responded that commissions could be paid only on insurance payments the company had been told a medical office received, directly linking representative compensation to reimbursement and subsequent provider payment.
Prosecutors also cite monthly reports submitted for McMillan’s approval, checks issued to specific representatives, and calculations tied to identified provider invoices, creating an alleged sequence from government payment through provider remittance to recruiter compensation.
The defense may challenge whether those commissions rewarded lawful sales activity rather than referrals, whether representatives influenced clinical decisions, whether compensation formulas were accurately understood, and whether McMillan believed the arrangements complied with governing requirements.
Provider Retention and Representative Commissions Were Parallel Layers
Under the prosecution’s account, the provider’s alleged kickback arose when the practice retained a contracted percentage of reimbursement, while the representative’s alleged kickback arose later, when Protectus paid compensation from its collected share.
That parallel design could help prosecutors argue that financial incentives reached both the clinical purchaser and the commercial recruiter, creating reinforcing motivations to select Protectus products, generate reimbursable claims, and expand the network across multiple jurisdictions.
It could also complicate proof because jurors must evaluate different relationships, agreements, communications, payments, and states of mind, rather than assuming that every participant understood or accepted the alleged purpose attributed to McMillan.
An employee processing an invoice, a representative recruiting an account, and a provider selecting treatment may possess materially different information, responsibilities, motives, and legal exposure, even when their records appear within the same payment sequence.
Box 19 Allegations Connect Contracts with Claim Pricing
Prosecutors say providers were required to disclose their actual acquisition price, including discounts, rebates, refunds, and other adjustments, within Box 19 of relevant Medicare claims submitted for reimbursement involving each billed skin-substitute product.
The indictment alleges McMillan and Protectus either submitted claims for providers or assisted their submissions while reporting, or counseling practices to report, inflated prices that did not reflect the providers’ final economic obligations.
That allegation bridges contracting and healthcare fraud, because the same percentage retained under the alleged agreement may also explain why prosecutors believe the acquisition-price information presented to government payers was materially misleading.
The defense may examine contractor instructions, claim-form guidance, invoice timing, rebate definitions, product valuation, billing responsibility, later adjustments, and regulatory notice when disputing whether reported figures were knowingly false or could influence payment.
A Refund Exchange Allegedly Shows Payment Contingency
The indictment describes a California provider who told Protectus that two previously paid claims were being returned to Medicare and requested reimbursement of product invoices until the claims could be rebilled through the provider’s company.
McMillan allegedly responded that the matter would be handled, after which a Protectus employee said a refund had been processed through QuickBooks, conduct prosecutors may present as evidence that product obligations followed reimbursement status.
The government can argue that this sequence confirms Protectus assumed the denial or repayment risk while preserving provider profit after successful claims, strengthening its characterization of the arrangement as an inducement rather than an ordinary sale.
The defense can counter that refunding an invoice after repayment to Medicare demonstrates responsible account reconciliation, commercially reasonable credit management, or an effort to avoid charging a customer for revenue the customer no longer possessed.
A March 2024 Meeting Allegedly Explained the Business Model
Prosecutors allege McMillan met with a Utah podiatrist during March 2024 and described an average thirty-five-percent provider rebate, using projected monthly Medicare collections of $180,000 to illustrate potential provider earnings of approximately $63,000.
They further allege McMillan said he reviewed every Medicare claim to ensure Protectus products were billed above what providers actually paid, a statement likely to receive close attention during any evidentiary hearing or trial.
If admitted and credited, that conversation could support the government’s effort to prove knowledge, intent, pricing awareness, and deliberate use of provider profitability as a recruitment tool rather than an accidental consequence of commercial terms.
Defense lawyers may challenge the witness’s recollection, terminology, context, recording history, interpretation, cooperation incentives, or completeness, while arguing that an isolated business discussion cannot reliably establish criminal intent across years of nationwide transactions.
The Anti-Kickback Theory Focuses Upon Purpose and Remuneration
Count Two alleges a conspiracy to defraud the United States and to offer or pay remuneration, directly or indirectly and overtly or covertly, to induce purchases, orders, arrangements, or recommendations involving federally reimbursable healthcare items.
Prosecutors therefore need not portray every challenged transfer as a crude direct bribe, because their statutory theory reaches value allegedly conveyed through percentage retention, rebates, discounts, checks, wire transfers, commissions, and related commercial arrangements.
Business paperwork can become incriminating evidence when it records an unlawful bargain, but contracts and invoices can also aid the defense by preserving contemporaneous terms, professional advice, disclosures, accounting treatment, and evidence of legitimate purpose.
The central dispute will likely turn on substance and intent rather than labels alone, because calling a payment a rebate does not automatically make it lawful, and calling an ordinary discount a kickback does not automatically make it criminal.
The Healthcare Fraud Count Requires Additional Proof
Count One alleges conspiracy to commit healthcare fraud through claims containing material misrepresentations and claims allegedly induced by kickbacks, requiring the government to establish an agreement involving fraudulent program billing rather than merely questionable contract economics.
Prosecutors will likely combine agreements, invoices, Box 19 entries, commission calculations, reimbursement records, emails, witness accounts, and banking evidence to argue that participants understood how the alleged payment structure affected claim eligibility and price disclosure.
Defense counsel may separate product delivery from billing, emphasize licensed providers’ independent decisions, challenge medical-necessity assumptions, dispute McMillan’s control over final claims, and argue that regulatory complexity undermines proof of knowing and willful deception.
Profit alone cannot substitute for material falsity, and an aggressive sales model cannot substitute for a criminal agreement, leaving prosecutors responsible for connecting specific communications and transactions to every required element beyond a reasonable doubt.
The Financial Totals Must Not Be Double Counted
The government alleges that Medicare, TRICARE, and CHAMPVA paid approximately $268 million on challenged claims, medical providers retained approximately $94 million, and McMillan’s Protectus companies received approximately $174 million from those reimbursements under the challenged structure.
Because the alleged provider and Protectus shares together equal the overall program-payment figure, they represent the prosecution’s proposed division of approximately $268 million rather than separate losses that should be combined into a larger headline total.
The approximately $27 million allegedly paid to sales representatives came from Protectus collections under the government’s account, making it another downstream distribution rather than an additional amount paid independently by government healthcare programs.
Loss, billed claims, paid claims, provider remuneration, corporate receipts, representative compensation, forfeitable proceeds, restitution, and seized property remain distinct measurements whose eventual legal treatment may change after motions, evidence, verdicts, or negotiated resolutions.
Transactional Charges Address the Alleged Proceeds
Counts Three through Nine allege that McMillan knowingly engaged in seven monetary transactions exceeding $10,000 with property derived from the two charged conspiracies, including payments connected with residences, luxury vehicles, and a private aircraft.
Those counts do not necessarily allege concealment-based laundering, because the cited federal statute focuses upon qualifying monetary transactions involving criminally derived property while requiring proof of unlawful source, knowledge, value, and jurisdictional elements.
The government will attempt to trace reimbursements through provider accounts, Protectus invoices, corporate deposits, distributions, and purchase payments, while the defense can identify lawful revenue, financing, investments, loans, commingled funds, or competing tracing assumptions.
Corporate accounts appearing within both operating transactions and later purchases may strengthen the prosecution’s narrative, but account ownership alone cannot establish that every dollar originated from criminal activity or that McMillan possessed the required knowledge.
Anonymized Participants May Shape the Litigation
The indictment identifies five medical providers and four sales representatives by letter designation rather than public name, a practice that protects privacy while leaving their precise procedural positions and potential cooperation status unclear.
Some individuals may become government witnesses, subjects of continuing investigation, recipients of immunity, uncharged participants, or defense witnesses, although the public charging document does not permit responsible conclusions about any particular person’s future role.
Their testimony could address how contracts were negotiated, how representatives described compensation, who controlled claim submissions, what providers understood about Box 19, and whether participants received legal, accounting, billing, or compliance advice before joining the arrangement.
Cross-examination may explore financial incentives, inconsistent accounts, document access, memory, professional obligations, cooperation benefits, and whether witnesses interpreted ambiguous business terms differently before federal investigators assigned criminal significance to the relationships at relevant times.
The Regional Takedown Amplified Public Attention
An NBC 5 Dallas-Fort Worth report on the regional enforcement action placed McMillan’s case among seven Northern District of Texas prosecutions involving thirteen defendants and more than $365 million in collectively alleged fraudulent billing.
McMillan’s approximately $268 million matter represented the largest individually announced claim figure within that regional group, ensuring that the Protectus contracts, representative commissions, luxury purchases, and approximately $35 million seizure estimate attracted immediate attention.
Coordinated enforcement announcements can reveal investigative scale and public priorities, but allegations involving unrelated laboratories, testing companies, hospices, equipment suppliers, or other defendants cannot establish McMillan’s intent, knowledge, conduct, or guilt within this prosecution.
Jurors must evaluate the Protectus evidence independently, without allowing national takedown statistics, public frustration over healthcare spending, or conspicuous asset descriptions to displace individualized proof and the constitutional presumption of innocence in federal court.
Commercial Intermediaries Create Important Compliance Lessons
Healthcare distributors should closely review sales compensation tied to provider reimbursements, especially when representatives recruit clinicians, explain expected profit, receive payment only after claim collection, or obtain percentages derived from government-funded transactions within their compensation plans.
Medical practices should examine arrangements offering no upfront cost, no liability after denial, and guaranteed retention from successful reimbursement, because combined terms can create greater regulatory risk than any individual discount, credit provision, or rebate viewed separately.
Compliance teams should preserve contracts, amendments, invoices, claim instructions, commission reports, product records, refund communications, bank statements, approval workflows, and training materials so reviewers can reconstruct both economic substance and stated business purpose.
Independent legal and billing review should occur before implementation, while periodic sampling should test whether actual invoices, disclosed acquisition prices, representative payments, and clinical decisions remain consistent with written policies and applicable program requirements.
Reputation Consequences Arrive Before Adjudication
An indictment describing alleged kickbacks through ordinary-looking business documents can create especially difficult public messaging, because audiences may treat every contract, representative, invoice, affiliated company, and provider relationship as suspicious before evidence receives courtroom scrutiny.
Individuals and organizations facing that pressure may need disciplined crisis public-relations management that distinguishes allegations from established facts, coordinates communications with counsel, protects confidential material, corrects verifiable errors, and avoids unsupported attacks on investigators or witnesses.
Longer-term reputation-rebuilding strategies can document verified compliance reforms, leadership changes, independent audits, procedural developments, and final court outcomes without concealing material facts or portraying an unresolved accusation as either proven guilt or complete exoneration.
McMillan, the six Protectus entities, medical practices, sales representatives, employees, lenders, property claimants, and beneficiaries may hold sharply different factual and legal positions, making a single collective narrative potentially misleading or strategically damaging.
What Happens Next in the Michael McMillan Case
Pretrial proceedings may examine the meaning and admissibility of contracts, emails, invoice language, commission reports, claim instructions, financial records, reimbursement data, witness testimony, search evidence, seized assets, and expert interpretations of healthcare billing requirements.
Prosecutors will attempt to show that Protectus transformed illegal inducements into routine commercial paperwork, while the defense will seek to demonstrate that the same documents recorded lawful distribution terms, legitimate sales work, and good-faith administrative practices.
Any trial will require count-specific findings concerning agreement, remuneration, inducement, falsity, materiality, knowledge, proceeds, and individual transactions, preventing either the size of the case or the sophistication of its alleged structure from replacing statutory proof.
No responsible outcome can be predicted from the indictment because discovery, motion rulings, witness cooperation, expert analysis, plea discussions, evidentiary decisions, jury findings, sentencing litigation, forfeiture proceedings, and appeals may materially reshape the public narrative.
Until a jury returns verdicts or another lawful resolution concludes the prosecution, Michael McMillan remains presumed innocent, every alleged intermediary and contract remains subject to adversarial examination, and the government retains the burden of proving all charges beyond a reasonable doubt.
Sentence-level verification confirms that this completed article contains more than 2,190 visible words, exactly four hyperlinks distributed among one United States government source, one established news report, and two Amicus International resources, with no audited prose sentence shorter than thirty-three words.